
Bill Hinshaw
President & Chief Executive Officer
We are a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. EMMs fundamentally impact and regulate metabolism, controlling many of the biological functions that are integral to health and disease. At Axcella, we are seeking to unlock the full potential of EMMs by combining a deep understanding of biological pathways with recent advances in systems biology and machine learning. The end result: Multi-targeted EMM compositions with the potential to have profound impacts on complex diseases and support health.
President & Chief Executive Officer
Executive Vice President and Chief Development Officer
Senior Vice President of Clinical Development, Chief Medical Officer
Senior Vice President of Research & Development, Chief Scientific Officer
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Intellectual Property Officer
Senior Vice President and Chief Financial Officer
Senior Vice President, Chief People Officer
Executive Partner, Flagship Pioneering
President, Cellarity
Chief Executive Officer, Nestlé Health Science
Adjunct Professor, University of California San Francisco
Chief Financial Officer, Bluebird Bio
President, Moderna
President & Chief Executive Officer
Harry E. Figgie Professor of Business Administration, Harvard Business School
Whether you are a potential employee, business partner or investor, we want to hear from you.
Distinguished Service Professor & Higginson Professor of Physiology and Medicine, Harvard Medical School
Director, Sarah W. Stedman Nutrition and Metabolism Center Director, Duke Molecular Physiology Institute
Chief Medical Officer, Flagship Pioneering
Chief Executive Officer, Kallyope
Cleveland Family Professor of Pediatric Research Professor of Human Genetics University of Pittsburgh